论文部分内容阅读
目的观察左卡尼汀治疗慢性肾衰竭血液透析患者的贫血及高脂血症的疗效。方法将42例慢性肾衰竭血液透析患者随机分成治疗组和对照组,两组患者均于血液透析后皮下注射促红细胞生成素,剂量为每周80~120 U/kg,待血红蛋白(Hb)>11 g/dl或血细胞比容(Hct)上升至33%后减量。同时治疗组每次血液透析后静脉注射左卡尼汀1.0g,疗程12周。结果治疗组的Hb、Hct水平显著高于对照组(P<0.05)。治疗组于治疗后第12周促红细胞生成素用量较治疗前减少。同时治疗组的胆固醇(TC)、甘油三酯(TG)水平较治疗前下降。结论左卡尼汀能提高促红细胞生成素治疗肾性贫血的疗效,同时改善慢性肾衰竭患者脂代谢紊乱。
Objective To observe the effect of levocarnitine on anemia and hyperlipidemia in hemodialysis patients with chronic renal failure. Methods 42 cases of hemodialysis patients with chronic renal failure were randomly divided into treatment group and control group. Both groups received subcutaneous injection of erythropoietin after hemodialysis at the dosage of 80 ~ 120 U / kg per week. When hemoglobin> 11 g / dl or hematocrit (Hct) increased to 33% after the reduction. At the same time, the treatment group was given L-carnitine 1.0 g intravenously after hemodialysis for 12 weeks. Results The levels of Hb and Hct in the treatment group were significantly higher than those in the control group (P <0.05). The treatment group at the 12th week after treatment erythropoietin dosage decreased compared with before treatment. At the same time, the levels of cholesterol (TC) and triglyceride (TG) in the treatment group decreased compared with those before treatment. Conclusion L-carnitine can improve the therapeutic effect of erythropoietin on renal anemia, and at the same time improve the disturbance of lipid metabolism in patients with chronic renal failure.